MX2023000041A - Composiciones y metodos para inducir una respuesta inmunitaria contra coronavirus. - Google Patents
Composiciones y metodos para inducir una respuesta inmunitaria contra coronavirus.Info
- Publication number
- MX2023000041A MX2023000041A MX2023000041A MX2023000041A MX2023000041A MX 2023000041 A MX2023000041 A MX 2023000041A MX 2023000041 A MX2023000041 A MX 2023000041A MX 2023000041 A MX2023000041 A MX 2023000041A MX 2023000041 A MX2023000041 A MX 2023000041A
- Authority
- MX
- Mexico
- Prior art keywords
- immune response
- inducing
- coronavirus
- methods
- compositions
- Prior art date
Links
- 241000711573 Coronaviridae Species 0.000 title abstract 3
- 230000028993 immune response Effects 0.000 title abstract 3
- 230000001939 inductive effect Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical group 0.000 abstract 2
- 108700002099 Coronavirus Nucleocapsid Proteins Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063044773P | 2020-06-26 | 2020-06-26 | |
| US202063064836P | 2020-08-12 | 2020-08-12 | |
| US202063124200P | 2020-12-11 | 2020-12-11 | |
| US202163145200P | 2021-02-03 | 2021-02-03 | |
| PCT/US2021/039134 WO2021263131A1 (en) | 2020-06-26 | 2021-06-25 | Compositions and methods for inducing an immune response against coronavirus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023000041A true MX2023000041A (es) | 2023-03-10 |
Family
ID=79281915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023000041A MX2023000041A (es) | 2020-06-26 | 2021-06-25 | Composiciones y metodos para inducir una respuesta inmunitaria contra coronavirus. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230263882A1 (https=) |
| EP (1) | EP4171574A4 (https=) |
| JP (1) | JP2023532290A (https=) |
| KR (1) | KR20230044404A (https=) |
| AU (1) | AU2021294342A1 (https=) |
| BR (1) | BR112022026580A2 (https=) |
| CA (1) | CA3183735A1 (https=) |
| MX (1) | MX2023000041A (https=) |
| WO (1) | WO2021263131A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI884296B (zh) * | 2020-08-11 | 2025-05-21 | 美商碩騰服務公司 | 抗冠狀病毒疫苗 |
| CA3170743A1 (en) * | 2020-08-31 | 2022-03-03 | Susanne RAUCH | Multivalent nucleic acid based coronavirus vaccines |
| WO2023114570A1 (en) * | 2021-12-19 | 2023-06-22 | Massachusetts Institute Of Technology | Compositions and methods for long-lasting germinal center responses to a priming immunization |
| WO2023159081A2 (en) * | 2022-02-15 | 2023-08-24 | Ohio State Innovation Foundation | Nanotechnology based intranasal vaccine for covid-19 |
| CN114752631B (zh) * | 2022-06-15 | 2022-09-02 | 中国人民解放军军事科学院军事医学研究院 | Rna及包含其的新型冠状病毒疫苗和制备方法 |
| WO2024226775A2 (en) * | 2023-04-26 | 2024-10-31 | Elicio Therapeutics, Inc. | Compositions containing polynucleotide and polypeptide amphiphiles and methods of use thereof |
| WO2025240477A1 (en) * | 2024-05-17 | 2025-11-20 | The Regents Of The University Of California | Methods and materials for enhancing delivery of nucleic acid to cells |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1629104A4 (en) * | 2003-06-04 | 2006-11-02 | Bioleaders Corp | CELL SURFACE EXPRESSION VECTOR OF SARS VIRUS ANTIGEN AND TRANSFORMED MICROORGANISMS |
| WO2006009011A1 (ja) * | 2004-07-15 | 2006-01-26 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | コロナウイルススパイクｓ１融合蛋白及びその発現ベクター |
| JP6375289B2 (ja) * | 2012-04-05 | 2018-08-15 | マサチューセッツ インスティテュート オブ テクノロジー | 免疫刺激組成物およびその使用方法 |
| JP6487850B2 (ja) * | 2013-11-29 | 2019-03-20 | テルモ株式会社 | アジュバント組成物およびこれを含むワクチン組成物、並びにこれらの製造方法 |
| DK3758712T3 (da) * | 2018-03-02 | 2025-08-04 | Elicio Therapeutics Inc | Cpg-amfifiler og anvendelser deraf |
| JP7438604B2 (ja) * | 2020-02-07 | 2024-02-27 | モデルナティエックス インコーポレイテッド | ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン |
-
2021
- 2021-06-25 AU AU2021294342A patent/AU2021294342A1/en not_active Abandoned
- 2021-06-25 CA CA3183735A patent/CA3183735A1/en active Pending
- 2021-06-25 JP JP2022580180A patent/JP2023532290A/ja active Pending
- 2021-06-25 MX MX2023000041A patent/MX2023000041A/es unknown
- 2021-06-25 EP EP21829804.0A patent/EP4171574A4/en active Pending
- 2021-06-25 US US18/012,343 patent/US20230263882A1/en active Pending
- 2021-06-25 BR BR112022026580A patent/BR112022026580A2/pt not_active Application Discontinuation
- 2021-06-25 KR KR1020237002322A patent/KR20230044404A/ko active Pending
- 2021-06-25 WO PCT/US2021/039134 patent/WO2021263131A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA3183735A1 (en) | 2021-12-30 |
| EP4171574A1 (en) | 2023-05-03 |
| JP2023532290A (ja) | 2023-07-27 |
| AU2021294342A1 (en) | 2023-02-23 |
| EP4171574A4 (en) | 2024-10-23 |
| BR112022026580A2 (pt) | 2023-01-24 |
| US20230263882A1 (en) | 2023-08-24 |
| KR20230044404A (ko) | 2023-04-04 |
| WO2021263131A1 (en) | 2021-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023000041A (es) | Composiciones y metodos para inducir una respuesta inmunitaria contra coronavirus. | |
| MX2024009072A (es) | Vacuna contra el coronavirus. | |
| PH12021550580A1 (en) | African swine fever virus vaccine | |
| MX2023000411A (es) | Vacuna combinada de sars-cov-2 e influenza. | |
| WO2023094713A3 (en) | Coronavirus vaccine | |
| Boyoglu-Barnum et al. | Prophylaxis with a respiratory syncytial virus (RSV) anti-G protein monoclonal antibody shifts the adaptive immune response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c mice | |
| EA202090738A1 (ru) | Способ безопасного индуцирования иммунитета против rsv | |
| WO2023147092A3 (en) | Coronavirus vaccine | |
| MX2021015465A (es) | Vacuna para fiebre porcina africana. | |
| MX2011006846A (es) | Virus de fiebre porcina clasico recombinante (csfv) comprendiendo una proteina e2 modificada y metodos para generar dicho csfv. | |
| EP1917033A4 (en) | VIRUS LIKE PARTICLES AS PARAMYXOVIRUS VACCINES | |
| MX342639B (es) | Virus de la influenza recombinantes de alta titulacion para vacunas y terapia genica. | |
| MX2022012251A (es) | Vacuna universal contra la influenza usando arnm modificado con nucleósidos. | |
| MX2022010588A (es) | Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2. | |
| MX2019003682A (es) | Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas. | |
| NO20082149L (no) | Hundeinfluensavirus og relaterte sammensetninger og fremgangsmater for bruk | |
| WO2021257510A3 (en) | Measles virus vaccine expressing sars-cov-2 protein(s) | |
| MX2022014167A (es) | Replicón de arn que codifica una proteína de espícula del coronavirus estabilizada. | |
| WO2005081716A3 (en) | DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV) | |
| MX2024006506A (es) | Vacunas basadas en vectores virales de metapneumovirus humano. | |
| WO2022103929A3 (en) | Nucleic acids, proteins, and vaccines of sars-cov-2 | |
| MX2023012368A (es) | Vacuna de virus. | |
| MX390966B (es) | Vacunas contra el dengue | |
| DK1610817T3 (da) | Infektiøs bronkitis virus med et ændret spike-gen | |
| MX2023002969A (es) | Mejora de la inmunidad usando un ligando quimerico del cumulo de diferenciacion 40 (cd40) y vacuna contra el coronavirus. |